Trials / Conditions / Encephalitis, Tick-Borne

Encephalitis, Tick-Borne

18 registered clinical trials studyying Encephalitis, Tick-Borne.

Status	Trial	Sponsor	Phase
Withdrawn	Fever After Tick Bite Study NCT03932448	Göteborg University	—
Terminated	Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) NCT01031537	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children NCT00894686	Pfizer	Phase 4
Completed	Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Sch NCT00840801	Pfizer	Phase 3
Completed	TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) NCT00503529	Pfizer	Phase 4
Completed	Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine Af NCT00452621	Novartis	Phase 4
Completed	Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Ra NCT00460486	Pfizer	Phase 3
Completed	Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults NCT00311493	Novartis	Phase 4
Completed	Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination W NCT00163618	Pfizer	—
Completed	Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinate NCT00163540	Pfizer	Phase 4
Completed	TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) NCT00161967	Pfizer	Phase 4
Completed	Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children NCT00311441	Novartis	Phase 4
Completed	Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged NCT00161954	Pfizer	Phase 4
Completed	FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years NCT00161876	Pfizer	Phase 3
Completed	FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years NCT00161889	Pfizer	Phase 2
Completed	FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years NCT00161850	Pfizer	Phase 2
Completed	Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR NCT00161824	Pfizer	Phase 3
Completed	Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 NCT00161746	Pfizer	Phase 2 / Phase 3